NCT04948203View on ClinicalTrials.gov

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

July 9, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Pulmonary FibrosisCOVID-19 PneumoniaLong COVID

Interventions

DRUG

Sirolimus

Triangular-shaped tablet

Trial Locations (1)

60637

University of Chicago, Chicago

All Listed Sponsors

lead

University of Chicago

OTHER